Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...

Panelist discusses how talquetamab’s step-up dosing strategy aims to mitigate cytokine release syndrome, a common immunologic toxicity. The reported grade 1 CRS with altered taste and dry mouth ...

Panelist discusses how the MonumenTAL-1 study led to the approval of talquetamab in patients with 4 or more prior lines of ...

Findings from the BOREAS study showed that navtemadlin as a monotherapy led to safety and efficacy in patients with ...

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...